Shares of BioNTech SE (NASDAQ:BNTX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seventeen research firms that are currently covering the firm, Marketbeat ...

The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

Bambusa Therapeutics raises $90M Series A for bispecific antibodies, led by RA Capital. Founded by BioNTech veterans, plans ...

Here is how Auna S.A. (AUNA) and BioNTech SE Sponsored ADR (BNTX) have performed compared to their sector so far this year.

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), with a price target ...

The Senate officially confirmed Robert F. Kennedy Jr.'s nomination as secretary of Health and Human Services on Thursday. The final vote count was 52 in favor and 48 against, with Sen. Mitch McConnell ...

BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

Vaccines are designed to guard babies, toddlers, and older children against a whole range of serious and potentially deadly ...

The overall market of herpes simplex is expected to boost with the expected launch of emerging therapy, increased awareness, and extensive research in the forecast period (2025-2034). LAS ...

Laura is an editor and staff writer at IFLScience. She obtained her Master's in Experimental Neuroscience from Imperial College London.